2024 APPlexus Bladder Cancer

CE / CME

Next-Generation Care for Patients With Bladder Cancer

Physician Assistants/Physician Associates: 1.00 AAPA Category 1 CME credit

Nurse Practitioners: 1.00 Nursing contact hours, includes 1.00 hour of pharmacotherapy credit

Released: June 05, 2024

Expiration: May 15, 2025

Beth Faiman
Beth Faiman, PhD, MSN, APN-BC, AOCN, BMTCN, FAAN, FAPO
Colleen H. Tetzlaff
Colleen H. Tetzlaff, MHS, PA-C

Pretest

Progress
1 2 3
Course Completed
Please answer the questions below.
1.

Case Study: 70-Yr-Old With Non-Muscle-Invasive BC​



  • 70-yr-old man with past medical history of non-muscle-invasive BC treated with BCG​

    • Comorbidities: HTN, abdominal aortic aneurism​



  • Recent transurethral resection of bladder tumor high-grade muscle-invasive BC​

  • CT scan shows metastases to lung and retroperitoneal lymph node​

  • ECOG PS 1​

  • CrCl: 61 mL/min​

  • PD-L1 status: high (TPS > 50%)​ ​

Which of the following would be an optimal first-line treatment in this patient considering the impact of toxicity profiles and his comorbidities?

2.

Which of the following would you recommend for a patient receiving T-DXd for recurrent HER2-positive bladder cancer who develops treatment-related asymptomatic grade 1 pneumonitis?